SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers
Public ClinicalTrials.gov record NCT03138408. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open Label, Phase 1 Study of SC-004 as Monotherapy and in Combination With ABBV-181 in Subjects With Epithelial Ovarian, Including Fallopian Tube and Primary Peritoneal and Endometrial Cancers
Study identification
- NCT ID
- NCT03138408
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 24 participants
Conditions and interventions
Conditions
Interventions
- ABBV-181 Drug
- SC-004 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 13, 2017
- Primary completion
- May 1, 2019
- Completion
- May 1, 2019
- Last update posted
- May 13, 2019
2017 – 2019
United States locations
- U.S. sites
- 12
- U.S. states
- 12
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama /ID# 202249 | Birmingham | Alabama | 35294 | — |
| Highlands Oncology Group /ID# 209165 | Fayetteville | Arkansas | 72703-4005 | — |
| City of Hope /ID# 202493 | Duarte | California | 91010 | — |
| University of Chicago /ID# 200735 | Chicago | Illinois | 60637 | — |
| Henry Ford Health System /ID# 202480 | Detroit | Michigan | 48202 | — |
| Mayo Clinic - Rochester /ID# 200732 | Rochester | Minnesota | 55905-0001 | — |
| Washington University School /ID# 164091 | St Louis | Missouri | 63108 | — |
| The Ohio State University - Columbus /ID# 164089 | Columbus | Ohio | 43210 | — |
| Univ Oklahoma HSC /ID# 164090 | Oklahoma City | Oklahoma | 73104 | — |
| Tennessee Oncology-Nashville Centennial /ID# 164088 | Nashville | Tennessee | 37203-1632 | — |
| MD Anderson Cancer Center /ID# 200048 | Houston | Texas | 77030 | — |
| Huntsman Cancer Institute /ID# 209164 | Salt Lake City | Utah | 84112-5500 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03138408, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 13, 2019 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03138408 live on ClinicalTrials.gov.